Adding an experimental drug to standard treatment more than doubles the likelihood of knocking out hepatitis C in patients with the chronic liver infection, two studies in the March 31 New England Journal of Medicine show.
The new drug, boceprevir, and a similar drug called telaprevir (SN: 5/23/09, p.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.